Literature DB >> 27058161

Distress Intolerance and Prescription Opioid Misuse Among Patients With Chronic Pain.

R Kathryn McHugh1, Roger D Weiss2, Marise Cornelius3, Marc O Martel4, Robert N Jamison5, Robert R Edwards5.   

Abstract

UNLABELLED: The risk for misuse of opioid medications is a significant challenge in the management of chronic pain. The identification of those who may be at greater risk for misusing opioids is needed to facilitate closer monitoring of high-risk subgroups, and may help to identify therapeutic targets for mitigating this risk. The aim of this study was to examine whether distress intolerance-the perceived or actual inability to manage negative emotional and somatic states-was associated with opioid misuse in those with chronic pain. A sample of 51 participants prescribed opioid analgesics for chronic back or neck pain were recruited for a 1-time laboratory study. Participants completed measures of distress intolerance and opioid misuse, and a quantitative sensory testing battery. Results suggested that distress intolerance was associated with opioid misuse, even controlling for pain severity and negative affect. Distress intolerance was not associated with pain severity, threshold, or tolerance, but was associated with self-reported anxiety and stress after noxious stimuli. This study found robust differences in distress intolerance between adults with chronic pain with and without opioid medication misuse. Distress intolerance may be a relevant marker of risk for opioid misuse among those with chronic pain. PERSPECTIVE: This study demonstrated that distress intolerance was associated with opioid misuse in adults with chronic pain who were prescribed opioids. Distress intolerance can be modified with treatment, and thus may be relevant not only for identification of risk for opioid misuse, but also for mitigation of this risk.
Copyright © 2016 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Opioids; chronic pain; distress tolerance; opioid misuse

Mesh:

Substances:

Year:  2016        PMID: 27058161      PMCID: PMC4925301          DOI: 10.1016/j.jpain.2016.03.004

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  47 in total

1.  Relations between anxiety sensitivity, distress tolerance, and fear reactivity to bodily sensations to coping and conformity marijuana use motives among young adult marijuana users.

Authors:  Michael J Zvolensky; Erin C Marshall; Kirsten Johnson; Julianna Hogan; Amit Bernstein; Marcel O Bonn-Miller
Journal:  Exp Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.157

2.  Development and preliminary randomized controlled trial of a distress tolerance treatment for smokers with a history of early lapse.

Authors:  Richard A Brown; Kathleen M Palm Reed; Erika Litvin Bloom; Haruka Minami; David R Strong; Carl W Lejuez; Christopher W Kahler; Michael J Zvolensky; Elizabeth V Gifford; Steven C Hayes
Journal:  Nicotine Tob Res       Date:  2013-07-24       Impact factor: 4.244

3.  Intolerance for Smoking Abstinence Questionnaire: psychometric properties and relationship to tobacco dependence and abstinence.

Authors:  Alan D Sirota; Damaris J Rohsenow; Selene V Mackinnon; Rosemarie A Martin; Cheryl A Eaton; Gary B Kaplan; Peter M Monti; Jennifer W Tidey; Robert M Swift
Journal:  Addict Behav       Date:  2010-03-02       Impact factor: 3.913

4.  Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria.

Authors:  Joseph A Boscarino; Margaret R Rukstalis; Stuart N Hoffman; John J Han; Porat M Erlich; Stephen Ross; Glenn S Gerhard; Walter F Stewart
Journal:  J Addict Dis       Date:  2011 Jul-Sep

5.  Domain-general and domain-specific strategies for the assessment of distress intolerance.

Authors:  R Kathryn McHugh; Michael W Otto
Journal:  Psychol Addict Behav       Date:  2011-08-08

6.  Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history.

Authors:  Edward Michna; Edgar L Ross; Wilfred L Hynes; Srdjan S Nedeljkovic; Sharonah Soumekh; David Janfaza; Diane Palombi; Robert N Jamison
Journal:  J Pain Symptom Manage       Date:  2004-09       Impact factor: 3.612

7.  Gender differences in risk factors for aberrant prescription opioid use.

Authors:  Robert N Jamison; Stephen F Butler; Simon H Budman; Robert R Edwards; Ajay D Wasan
Journal:  J Pain       Date:  2009-11-27       Impact factor: 5.820

8.  Development and validation of the Current Opioid Misuse Measure.

Authors:  Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison
Journal:  Pain       Date:  2007-05-09       Impact factor: 6.961

9.  A prospective examination of distress tolerance and early smoking lapse in adult self-quitters.

Authors:  Richard A Brown; C W Lejuez; David R Strong; Christopher W Kahler; Michael J Zvolensky; Linda L Carpenter; Raymond Niaura; Lawrence H Price
Journal:  Nicotine Tob Res       Date:  2009-04-16       Impact factor: 4.244

10.  Changes in distress intolerance and treatment outcome in a partial hospital setting.

Authors:  R Kathryn McHugh; Sarah J Kertz; Rachel B Weiss; Arielle R Baskin-Sommers; Bridget A Hearon; Thröstur Björgvinsson
Journal:  Behav Ther       Date:  2013-11-13
View more
  31 in total

1.  Inhibitory transmission in the bed nucleus of the stria terminalis in male and female mice following morphine withdrawal.

Authors:  Brennon R Luster; Elizabeth S Cogan; Karl T Schmidt; Dipanwita Pati; Melanie M Pina; Kedar Dange; Zoé A McElligott
Journal:  Addict Biol       Date:  2019-04-09       Impact factor: 4.280

2.  Negative Affect-Related Factors Have the Strongest Association with Prescription Opioid Misuse in a Cross-Sectional Cohort of Patients with Chronic Pain.

Authors:  Gadi Gilam; John A Sturgeon; Dokyoung S You; Ajay D Wasan; Beth D Darnall; Sean C Mackey
Journal:  Pain Med       Date:  2020-02-01       Impact factor: 3.750

3.  Distress intolerance moderation of neurophysiological markers of response inhibition after induced stress: Relations with cannabis use disorder.

Authors:  Richard J Macatee; Brian J Albanese; Natania A Crane; Sarah A Okey; Jesse R Cougle; Norman B Schmidt
Journal:  Psychol Addict Behav       Date:  2018-11-08

4.  Emotion regulation and motives for illicit drug use in opioid-dependent patients.

Authors:  Alexandra K Gold; Georgia Stathopoulou; Michael W Otto
Journal:  Cogn Behav Ther       Date:  2019-02-14

Review 5.  Comorbidity of opioid-related and anxiety-related symptoms and disorders.

Authors:  Kirsten J Langdon; Kathrine Dove; Susan Ramsey
Journal:  Curr Opin Psychol       Date:  2019-01-04

6.  Anxiety sensitivity and opioid misuse among opioid-using adults with chronic pain.

Authors:  Andrew H Rogers; Brooke Y Kauffman; Jafar Bakhshaie; R Kathryn McHugh; Joseph W Ditre; Michael J Zvolensky
Journal:  Am J Drug Alcohol Abuse       Date:  2019-03-21       Impact factor: 3.829

7.  Distress Intolerance and Smoking Topography in the Context of a Biological Challenge.

Authors:  Samantha G Farris; Elizabeth R Aston; Teresa M Leyro; Lily A Brown; Michael J Zvolensky
Journal:  Nicotine Tob Res       Date:  2019-04-17       Impact factor: 4.244

8.  Pain catastrophizing and distress intolerance: prediction of pain and emotional stress reactivity.

Authors:  R Kathryn McHugh; Elizabeth T Kneeland; Robert R Edwards; Robert Jamison; Roger D Weiss
Journal:  J Behav Med       Date:  2019-08-02

9.  Divergent behavioral responses in protracted opioid withdrawal in male and female C57BL/6J mice.

Authors:  Isabel M Bravo; Brennon R Luster; Meghan E Flanigan; Patric J Perez; Elizabeth S Cogan; Karl T Schmidt; Zoe A McElligott
Journal:  Eur J Neurosci       Date:  2019-10-06       Impact factor: 3.386

Review 10.  Emotion regulation as a transdiagnostic factor underlying co-occurring chronic pain and problematic opioid use.

Authors:  Rachel V Aaron; Patrick H Finan; Stephen T Wegener; Francis J Keefe; Mark A Lumley
Journal:  Am Psychol       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.